Pub. Date : 2019 Dec
PMID : 31715421
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | RET fusions or rearrangements are somatic juxtapositions of 5" sequences from other genes with 3" RET sequences encoding tyrosine kinase. | Tyrosine | ret proto-oncogene | Homo sapiens |
| 2 | RET fusions or rearrangements are somatic juxtapositions of 5" sequences from other genes with 3" RET sequences encoding tyrosine kinase. | Tyrosine | ret proto-oncogene | Homo sapiens |
| 3 | Tyrosine kinase inhibitors are drugs that target kinases such as RET in RET-driven (RET-mutation or RET-fusion-positive) disease. | Tyrosine | ret proto-oncogene | Homo sapiens |
| 4 | Tyrosine kinase inhibitors are drugs that target kinases such as RET in RET-driven (RET-mutation or RET-fusion-positive) disease. | Tyrosine | ret proto-oncogene | Homo sapiens |
| 5 | Tyrosine kinase inhibitors are drugs that target kinases such as RET in RET-driven (RET-mutation or RET-fusion-positive) disease. | Tyrosine | ret proto-oncogene | Homo sapiens |
| 6 | Tyrosine kinase inhibitors are drugs that target kinases such as RET in RET-driven (RET-mutation or RET-fusion-positive) disease. | Tyrosine | ret proto-oncogene | Homo sapiens |
| 7 | RET fusions provide a viable therapeutic target for oncologic treatment, and further study is warranted into the prevalence and pathogenesis of RET fusions as well as development of current and new tyrosine kinase inhibitors. | Tyrosine | ret proto-oncogene | Homo sapiens |